<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00376038</url>
  </required_header>
  <id_info>
    <org_study_id>KG2105246</org_study_id>
    <nct_id>NCT00376038</nct_id>
  </id_info>
  <brief_title>Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Randomized Open-label, Repeat Dose, Two Sequence Cross-Over Study to Determine the Effect of GSK189075 on the Pharmacokinetic Parameters of Metformin (Glucophage) in Subjects With Type 2 Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      GSK189075 is intended for use as a single treatment or in combination with other treatments&#xD;
      for tye 2 diabetes mellitus (T2DM). Metformin is widely used in Europe and the USA for the&#xD;
      treatment of T2DM. This study will evaluate the effect of GSK189075 on metformin levels in&#xD;
      the blood in T2DM subjects. The rationale is to look for any safety problems that may result&#xD;
      when the 2 drugs are given together.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood concentrations of metformin when given with GSK189075 in T2DM subjects over 3-day course Lab tests, changes in blood pressure and heart rate and heart activity on EKG machine</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood levels of drugs at Day 3 Evaluation of efficacy and safety markers on Days 1, 2, and 3.</measure>
  </secondary_outcome>
  <enrollment type="Actual">13</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK189075 oral tablets</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin tablets</intervention_name>
    <other_name>GSK189075 oral tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Have Type 2 diabetes mellitus.&#xD;
&#xD;
          -  Have a Body Mass Index within range 22 to 35kg/m2 inclusive.&#xD;
&#xD;
          -  Females who meet above criteria must be physiologically incapable of becoming pregnant&#xD;
             (i.e., surgically sterilized, or post-menopausal per protocol definition).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Are currently taking insulin therapy.&#xD;
&#xD;
          -  Have any disease (such as heart, liver, blood, nervous system, or kidney disease, or&#xD;
             cancer).&#xD;
&#xD;
          -  Have a history of stomach, liver, kidney, or other disease that with interfere with&#xD;
             taking the study drug.&#xD;
&#xD;
          -  Are currently using diuretics, oral or injectable corticosteroids (inhaled &amp;&#xD;
             intranasal corticosteroids are permitted), or other medications that would cause you&#xD;
             to deplete your fluid balance in your body; currently taking stable regimens for heart&#xD;
             conditions; currently using prescription or non-prescription drugs within 7 days of&#xD;
             starting the study that may interfere with the study drug.&#xD;
&#xD;
          -  Would donate more than 450 ML of blood over a 2 month period.&#xD;
&#xD;
          -  Physician does not think it is a good idea for you to participate in the trial. - Had&#xD;
             a urinary tract infection or bladder infection in the last month. - Are currently&#xD;
             drinking more than 2 beers, 1 glass of wine, or 1 glass of spirits daily.&#xD;
&#xD;
          -  Have a positive urine drug screen test.&#xD;
&#xD;
          -  Plan to change your smoking habits during the course of the trial.&#xD;
&#xD;
          -  Have Hepatitis C, Hepatitis B, or HIV. - Have a lab or EKG abnormality. - High or low&#xD;
             blood pressure.&#xD;
&#xD;
          -  Have used of any investigational drug or device during the study or within 30 days&#xD;
             prior to 1st dosing of study medication.&#xD;
&#xD;
          -  Are a male subject unwilling to abstain or use protection during intercourse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico, D.F.</city>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>September 12, 2006</study_first_submitted>
  <study_first_submitted_qc>September 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2006</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK189074</keyword>
  <keyword>T2DM</keyword>
  <keyword>GSK189075</keyword>
  <keyword>Glucophage</keyword>
  <keyword>Obesity</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Metformin</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Drug Interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

